NEW YORK and BERLIN, June 01, 2023 atai Life Sciences , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in. | June 1, 2023
RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia.GRX-917: Presented PD data from the completed Phase 1 study, which suggest the. | May 11, 2023
Item 2.02. Results of Operations and Financial Condition.
On May 11, 2023, ATAI Life Sciences N.V. issued a press release
announcing its financial results for the quarter ended March 31, 2023. | May 11, 2023
NEW YORK and BERLIN, May 02, 2023 atai Life Sciences , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023. | May 2, 2023
- Pharmacodynamic profile of GRX-917 indicates potential for anxiolytic activity without the significant sedative side effects associated with benzodiazepines NEW YORK and BERLIN, April 28, 2023 . | April 28, 2023